CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML
ConditionAcute Myeloid Leukemia
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorNavy General Hospital, Beijing
About this trial
The goal of this phase 2 trial is to test the safety and efficacy of CHG Combined With Venetoclax in treating patients with newly diagnosed AML.
Eligibility criteria
Qualifiers
The patient should, in the investigator's opinion, be able to meet all clinical trial requirements.
The patient is willing and able to adhere to the study visit schedule and other protocol requirements.
The patient should be diagnosed with AML according to the standard criteria of the World Health Organisation (WHO).
The patient should not have received any prior treatment for AML.
Disqualifiers
Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.
Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.
Pregnant or lactating women.
Trial design
Treatments tested in this trial
- CHG Combined With Venetoclax and Azacytidine
Treatment groups
85 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov